The	O
symbiotic	O
bacterial	O
surface	O
factor	O
polysaccharide	O
A	O
on	O
Bacteroides	B-OG
fragilis	I-OG
inhibits	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
inflammation	O
in	O
human	B-OG
fetal	O
enterocytes	O
via	O
toll	B-GP
receptors	I-GP
2	I-GP
and	O
4	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceptualization	O
:	O
WAW	O
DK	O
DM	O
MW	O
WW	O
.	O
Data	O
curation	O
:	O
FJ	O
DM	O
MW	O
WZ	O
.	O
Formal	O
analysis	O
:	O
WAW	O
DM	O
MW	O
.	O
Funding	O
acquisition	O
:	O
WAW	O
WW	O
.	O
Investigation	O
:	O
WAW	O
DM	O
FJ	O
MW	O
.	O
Methodology	O
:	O
WAW	O
DM	O
FJ	O
MW	O
.	O
Project	O
administration	O
:	O
WAW	O
.	O
Resources	O
:	O
WAW	O
DK	O
.	O
Software	O
:	O
WAW	O
.	O
Supervision	O
:	O
WAW	O
.	O
Validation	O
:	O
WAW	O
.	O
Visualization	O
:	O
WAW	O
DM	O
.	O
Writing	O
–	O
original	O
draft	O
:	O
DM	O
WAW	O
MW	O
.	O
Writing	O
–	O
review	O
&	O
editing	O
:	O
WAW	O
.	O

‡	O
These	O
authors	O
are	O
co	O
-	O
first	O
authors	O
on	O
this	O
work	O
.	O

Colonizing	O
bacteria	B-OG
interacting	O
with	O
the	O
immature	O
,	O
unlike	O
the	O
mature	O
,	O
human	B-OG
intestine	O
favors	O
inflammation	O
over	O
immune	O
homeostasis	O
.	O

As	O
a	O
result	O
,	O
ten	O
percent	O
of	O
premature	O
infants	O
under	O
1500	O
grams	O
weight	O
develop	O
an	O
inflammatory	O
necrosis	O
of	O
the	O
intestine	O
after	O
birth	O
,	O
e	O
.	O
g	O
.,	O
necrotizing	B-DS
enterocolitis	I-DS
(	O
NEC	B-DS
).	O

NEC	B-DS
is	O
a	O
major	O
health	O
problem	O
in	O
this	O
population	O
causing	O
extensive	O
morbidity	O
and	O
mortality	O
and	O
an	O
enormous	O
expenditure	O
of	O
health	O
care	O
dollars	O
.	O

NEC	B-DS
can	O
be	O
prevented	O
by	O
giving	O
preterm	O
infants	O
their	O
mother	O
’	O
s	O
expressed	O
breast	O
milk	O
or	O
ingesting	O
selective	O
probiotic	B-OG
organisms	I-OG
.	O

Vaginally	O
delivered	O
,	O
breast	O
fed	O
newborns	O
develop	O
health	O
promoting	O
bacteria	B-OG
(“	O
pioneer	O
”	O
bacteria	B-OG
)	O
which	O
preferentially	O
stimulate	O
intestinal	O
host	O
defense	O
and	O
anti	O
-	O
inflammation	O
.	O

One	O
such	O
“	O
pioneer	O
”	O
organism	O
is	O
Bacteroides	B-OG
fragilis	I-OG
with	O
a	O
polysaccharide	O
(	O
PSA	O
)	O
on	O
its	O
capsule	O
.	O
B	B-OG
.	I-OG
fragilis	I-OG
has	O
been	O
shown	O
developmentally	O
in	O
intestinal	O
lymphocytes	O
and	O
dendritic	O
cells	O
to	O
produce	O
a	O
balanced	O
T	O
-	O
helper	O
cell	O
(	O
TH1	O
/	O
TH2	O
)	O
response	O
and	O
to	O
reduce	O
intestinal	O
inflammation	O
by	O
activity	O
through	O
the	O
TLR2	B-GP
receptor	I-GP
stimulating	O
IL	B-GP
-	I-GP
10	I-GP
which	O
inhibits	O
IL	B-GP
-	I-GP
17	I-GP
causing	O
inflammation	O
.	O

No	O
studies	O
have	O
been	O
done	O
on	O
the	O
role	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
on	O
fetal	O
enterocytes	O
and	O
its	O
increased	O
inflammation	O
.	O

Accordingly	O
,	O
using	O
human	B-OG
and	O
mouse	B-OG
fetal	O
intestinal	O
models	O
,	O
we	O
have	O
shown	O
that	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
and	O
PSA	O
alone	O
inhibits	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
IL	B-GP
-	I-GP
8	I-GP
inflammation	O
in	O
fetal	O
and	O
NEC	B-DS
intestine	O
.	O

We	O
have	O
also	O
begun	O
to	O
define	O
the	O
mechanism	O
for	O
this	O
unique	O
inflammation	O
noted	O
in	O
fetal	O
intestine	O
.	O

We	O
have	O
shown	O
that	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
anti	O
-	O
inflammation	O
requires	O
both	O
the	O
TLR2	B-GP
and	O
TLR4	B-GP
receptor	I-GP
and	O
is	O
in	O
part	O
mediated	O
by	O
the	O
AP1	B-GP
transcription	B-GP
factor	I-GP
(	O
TLR2	B-GP
)	O
which	O
is	O
developmentally	O
regulated	O
.	O

These	O
observations	O
may	O
help	O
to	O
devise	O
future	O
preventative	O
treatments	O
of	O
premature	O
infants	O
against	O
NEC	B-DS
.	O

Introduction	O

Colonizing	O
bacteria	B-OG
interacting	O
with	O
the	O
immature	O
human	B-OG
intestine	O
,	O
unlike	O
the	O
mature	O
intestine	O
,	O
favors	O
inflammation	O
over	O
homeostasis	O
[	O
1	O
,	O
2	O
].	O

As	O
a	O
result	O
ten	O
percent	O
of	O
premature	O
infants	O
develop	O
an	O
inflammatory	O
necrosis	O
of	O
the	O
intestine	O
after	O
birth	O
,	O
a	O
condition	O
known	O
as	O
necrotizing	B-DS
enterocolitis	I-DS
(	O
NEC	B-DS
)	O
[	O
3	O
,	O
4	O
].	O

NEC	B-DS
is	O
a	O
major	O
health	O
problem	O
in	O
this	O
patient	O
population	O
causing	O
extensive	O
morbidity	O
and	O
mortality	O
and	O
an	O
enormous	O
expenditure	O
of	O
health	O
care	O
dollars	O
[	O
5	O
].	O

Yet	O
certain	O
commensal	B-OG
bacteria	I-OG
used	O
as	O
probiotics	O
,	O
when	O
given	O
to	O
newborn	O
prematures	O
can	O
prevent	O
or	O
lessen	O
the	O
severity	O
of	O
NEC	B-DS
[	O
6	O
,	O
7	O
].	O

What	O
is	O
it	O
about	O
the	O
immature	O
intestine	O
interacting	O
with	O
colonizing	O
bacteria	B-OG
that	O
causes	O
this	O
paradoxical	O
response	O
?	O

We	O
hypothesize	O
that	O
commensal	B-OG
bacteria	I-OG
interacting	O
with	O
immature	O
enterocytes	O
can	O
result	O
in	O
either	O
an	O
excessive	O
inflammatory	O
response	O
or	O
an	O
inhibition	O
of	O
inflammation	O
depending	O
on	O
the	O
composition	O
of	O
the	O
immature	O
signaling	O
pathways	O
in	O
the	O
enterocyte	O
.	O

Support	O
for	O
this	O
hypothesis	O
,	O
as	O
published	O
data	O
,	O
exists	O
from	O
this	O
laboratory	O
[	O
1	O
,	O
4	O
,	O
8	O
].	O

We	O
have	O
identified	O
that	O
the	O
genes	O
responsible	O
for	O
the	O
innate	O
immune	O
response	O
pathway	O
,	O
e	O
.	O
g	O
.,	O
NFκB	B-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
and	O
their	O
negative	O
regulators	O
(	O
SIGRR	B-GP
,	O
IRAK	B-GP
-	I-GP
M	I-GP
,	O
A20	B-GP
,	O
etc	O
.)	O
are	O
either	O
increased	O
(	O
NFκB	B-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
)	O
or	O
decreased	O
(	O
negative	O
regulators	O
SIGRR	B-GP
,	O
IRAK	B-GP
-	I-GP
M	I-GP
,	O
A20	B-GP
,	O
etc	O
.)	O
developmentally	O
causing	O
an	O
aberrant	O
response	O
to	O
these	O
bacteria	B-OG
[	O
8	O
–	O
10	O
].	O

We	O
have	O
also	O
shown	O
that	O
a	O
secreted	O
factor	O
from	O
Bifidobacterium	B-OG
infantis	I-OG
(	O
a	O
probiotic	O
preventative	O
of	O
NEC	B-DS
)	O
preferentially	O
downregulates	O
an	O
IL	B-GP
-	I-GP
1β	I-GP
inflammatory	O
stimulus	O
in	O
fetal	O
enterocytes	O
[	O
4	O
,	O
11	O
].	O

These	O
observations	O
suggest	O
that	O
immature	O
enterocytes	O
interacting	O
with	O
commensal	B-OG
bacteria	I-OG
or	O
their	O
secretions	O
have	O
unique	O
inflammatory	O
or	O
anti	O
-	O
inflammatory	O
pathways	O
.	O

In	O
fullterm	O
neonates	O
,	O
an	O
appropriate	O
initial	O
bacterial	O
colonization	O
of	O
the	O
intestine	O
is	O
necessary	O
for	O
normal	O
development	O
of	O
immune	O
defense	O
leading	O
to	O
homeostasis	O
[	O
12	O
].	O

Optimal	O
colonization	O
occurs	O
when	O
a	O
full	O
term	O
infant	O
is	O
born	O
vaginally	O
,	O
receiving	O
maternal	O
vaginal	O
/	O
colonic	O
microbiota	B-OG
.	O

The	O
initial	O
bolus	O
of	O
maternal	O
microbiota	B-OG
is	O
further	O
stimulated	O
by	O
oligosaccharides	O
and	O
other	O
active	O
factors	O
(	O
pIgA	B-GP
,	O
lactoferrin	B-GP
,	O
etc	O
.)	O
in	O
breast	O
milk	O
which	O
activate	O
proliferation	O
of	O
so	O
called	O
“	O
pioneer	O
”	O
bacteria	B-OG
,	O
essential	O
for	O
stimulus	O
of	O
gut	O
development	O
[	O
13	O
].	O

Such	O
“	O
pioneer	O
”	O
bacteria	B-OG
isolated	O
from	O
newborn	O
gut	O
have	O
been	O
shown	O
to	O
stimulate	O
the	O
development	O
of	O
sIgA	B-GP
production	O
[	O
14	O
]	O
and	O
to	O
reduce	O
excessive	O
intestinal	O
inflammation	O
[	O
15	O
].	O

One	O
such	O
“	O
pioneer	O
”	O
bacterium	B-OG
noted	O
in	O
infant	O
intestine	O
early	O
in	O
life	O
is	O
Bacteroides	B-OG
fragilis	I-OG
[	O
13	O
].	O

This	O
bacterium	B-OG
expresses	O
on	O
its	O
surface	O
a	O
polysaccharide	O
(	O
PSA	O
)	O
which	O
has	O
been	O
shown	O
to	O
affect	O
the	O
development	O
of	O
immune	O
function	O
[	O
14	O
]	O
in	O
macrophages	O
and	O
dendritic	O
cells	O
.	O

Polysaccharide	O
A	O
(	O
PSA	O
)	O
creates	O
a	O
balanced	O
TH1	O
/	O
TH2	O
helper	O
cell	O
response	O
which	O
may	O
prevent	O
the	O
development	O
of	O
allergy	B-DS
[	O
15	O
].	O

PSA	O
also	O
interacts	O
with	O
TLR2	B-GP
receptor	I-GP
molecules	O
on	O
CD4	B-GP
lymphocytes	O
to	O
preferentially	O
stimulate	O
T	O
-	O
regulatory	O
cells	O
to	O
produce	O
IL	B-GP
-	I-GP
10	I-GP
[	O
16	O
]	O
which	O
prevents	O
experimental	O
induced	O
colitis	B-DS
via	O
IL	B-GP
-	I-GP
17	I-GP
stimulation	O
[	O
17	O
,	O
18	O
].	O

To	O
date	O
no	O
studies	O
have	O
examined	O
the	O
effect	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
on	O
enterocytes	O
.	O

Since	O
this	O
organism	O
appears	O
early	O
in	O
the	O
newborn	O
intestine	O
and	O
is	O
anti	O
-	O
inflammatory	O
,	O
we	O
studied	O
its	O
effect	O
on	O
fetal	O
human	B-OG
enterocytes	O
as	O
a	O
possible	O
basis	O
for	O
prevention	O
of	O
NEC	B-DS
.	O

In	O
this	O
study	O
,	O
we	O
used	O
ex	O
vivo	O
models	O
of	O
human	B-OG
fetal	O
and	O
NEC	B-DS
intestine	O
and	O
fetal	O
mouse	B-OG
intestine	O
to	O
determine	O
the	O
mechanisms	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
inhibition	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
stimulated	O
inflammation	O
.	O

Materials	O
and	O
methods	O

Bacteroides	B-OG
fragilis	I-OG
and	O
polysaccharide	O
A	O
(	O
PSA	O
)	O

B	B-OG
.	I-OG
fragilis	I-OG
NCTC	I-OG
9343	I-OG
(	O
dossa	O
)	O
containing	O
PSA	O
on	O
its	O
capsule	O
and	O
a	O
mutant	O
strain	O
without	O
PSA	O
(	O
delta	O
)	O
were	O
provided	O
by	O
Dr	O
.	O
Dennis	O
Kasper	O
,	O
Department	O
of	O
Microbiology	O
and	O
Molecular	O
Genetics	O
,	O
Harvard	O
Medical	O
School	O
.	O

These	O
strains	O
have	O
been	O
previously	O
described	O
in	O
detail	O
[	O
19	O
].	O

The	O
organisms	O
were	O
grown	O
anaerobically	O
in	O
broth	O
culture	O
as	O
previously	O
described	O
[	O
20	O
]	O
until	O
they	O
reached	O
a	O
stationary	O
phase	O
of	O
growth	O
(	O
OD	O
600	O
>	O
1	O
.	O
0	O
).	O

Initially	O
,	O
H4	O
cells	O
,	O
a	O
human	B-OG
fetal	O
nontransformed	O
primary	O
small	O
intestinal	O
cell	O
line	O
characterized	O
by	O
our	O
laboratory	O
[	O
21	O
],	O
were	O
incubated	O
with	O
either	O
wildtype	O
B	B-OG
.	I-OG
fragilis	I-OG
(	O
PSA	O
dossa	O
)	O
or	O
mutant	O
B	B-OG
.	I-OG
fragilis	I-OG
(	O
PSA	O
delta	O
)	O
at	O
107	O
or	O
108	O
organisms	O
per	O
cc	O
in	O
media	O
for	O
one	O
hour	O
.	O

H4	O
cells	O
were	O
then	O
washed	O
with	O
PBS	O
and	O
incubated	O
in	O
the	O
medium	O
with	O
gentamicin	O
(	O
100	O
μg	O
/	O
ml	O
)	O
for	O
one	O
hour	O
,	O
washed	O
with	O
PBS	O
then	O
stimulated	O
with	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
5	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
in	O
the	O
media	O
containing	O
10	O
μg	O
/	O
ml	O
gentamicin	O
to	O
kill	O
extracellular	O
organisms	O
after	O
initial	O
interaction	O
.	O

The	O
supernatants	O
were	O
then	O
saved	O
for	O
ELISA	O
analysis	O
in	O
a	O
-	O
20	O
°	O
C	O
refrigerator	O
.	O

Purified	O
PSA	O
was	O
also	O
provided	O
by	O
Dr	O
.	O
Dennis	O
Kasper	O
.	O

PSA	O
has	O
previously	O
been	O
isolated	O
,	O
purified	O
and	O
characterized	O
from	O
B	B-OG
.	I-OG
fragilis	I-OG
NCTC	I-OG
9343	I-OG
as	O
reported	O
[	O
22	O
].	O

A	O
dose	O
response	O
curve	O
was	O
obtained	O
for	O
the	O
optimal	O
effect	O
of	O
PSA	O
on	O
H4	O
cells	O
and	O
on	O
organ	O
cultures	O
of	O
fetal	O
mouse	B-OG
intestine	O
.	O

H4	O
cells	O
were	O
incubated	O
with	O
purified	O
PSA	O
(	O
400	O
μg	O
/	O
cc	O
media	O
)	O
for	O
24	O
hrs	O
before	O
exposure	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
5	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
.	O

Supernatants	O
were	O
saved	O
at	O
-	O
20	O
°	O
C	O
for	O
ELISA	O
assay	O
.	O

H4	O
cell	O
line	O
subjected	O
to	O
TLR2	B-GP
and	O
TLR4	B-GP
siRNA	O
transfection	O

H4	O
cells	O
,	O
were	O
cultured	O
in	O
Dulbeco	O
’	O
modified	O
Eagle	O
’	O
s	O
medium	O
(	O
DMEM	O
)	O
(	O
Gibco	O
Thermofisher	O
,	O
Woburn	O
,	O
MA	O
)	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
(	O
Mediatech	O
,	O
Manassa	O
,	O
VA	O
),	O
0	O
.	O
2	O
u	O
/	O
ml	O
insulin	B-GP
(	O
Eli	O
Lilly	O
and	O
Company	O
,	O
Indianapolis	O
,	O
IN	O
),	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
0	O
.	O
1	O
mM	O
MEM	O
nonessential	O
amino	O
acids	O
,	O
10	O
mM	O
Hepes	O
buffer	O
,	O
100	O
units	O
/	O
ml	O
penicillin	O
and	O
100	O
μg	O
/	O
ml	O
streptomycin	O
(	O
all	O
purchased	O
from	O
Gibco	O
Thermofisher	O
).	O

H4	O
cells	O
were	O
transfected	O
with	O
stealth	O
human	B-OG
TLR2	B-GP
or	O
TLR4	B-GP
siRNA	O
or	O
control	O
siRNA	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
Invitrogen	O
Thermofisher	O
,	O
Grand	O
Island	O
,	O
NY	O
).	O

Briefly	O
,	O
for	O
each	O
well	O
of	O
6	O
-	O
well	O
plates	O
to	O
be	O
transfected	O
,	O
RNAi	O
and	O
Lipofectamine	O
RNAiMAX	O
complexes	O
were	O
prepared	O
as	O
follows	O
:	O
25	O
pmol	O
of	O
diluted	O
RNAi	O
in	O
400	O
μl	O
Opti	O
-	O
MEM	O
I	O
medium	O
without	O
serum	O
;	O
4	O
μl	O
of	O
Lipofectamine	O
RNAiMAX	O
was	O
added	O
to	O
each	O
well	O
containing	O
the	O
diluted	O
RNAi	O
molecules	O
and	O
incubated	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
.	O

3x105	O
H4	O
cells	O
were	O
added	O
in	O
600	O
μl	O
of	O
antibiotic	O
free	O
H4	O
growth	O
media	O
and	O
then	O
added	O
to	O
each	O
well	O
resulting	O
in	O
25nM	O
RNAi	O
in	O
the	O
culture	O
.	O

After	O
24	O
hrs	O
of	O
incubation	O
at	O
37	O
°	O
C	O
,	O
an	O
additional	O
1	O
ml	O
of	O
H4	O
growth	O
media	O
without	O
antibiotics	O
was	O
added	O
to	O
each	O
well	O
resulting	O
in	O
a	O
12	O
.	O
5	O
nM	O
final	O
concentration	O
.	O

All	O
transfection	O
reagents	O
were	O
purchased	O
from	O
Invitrogen	O
Thermofisher	O
.	O

Efficiency	O
was	O
analyzed	O
by	O
real	O
time	O
qRT	O
-	O
PCR	O
and	O
red	O
oligo	O
staining	O
72	O
hrs	O
after	O
the	O
transfection	O
(	O
the	O
knock	O
-	O
down	O
rate	O
was	O
71	O
.	O
6	O
%	O
TLR4	B-GP
,	O
94	O
%	O
TRL2	B-GP
and	O
transfection	O
-	O
rate	O
was	O
94	O
.	O
8	O
%).	O

The	O
cells	O
were	O
incubated	O
with	O
PSA	O
control	O
media	O
for	O
24	O
hrs	O
beginning	O
at	O
48	O
hrs	O
after	O
transfection	O
and	O
then	O
exposed	O
or	O
not	O
to	O
1ng	O
/	O
ml	O
of	O
recombinant	O
human	B-OG
IL	B-GP
-	I-GP
1β	I-GP
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
))	O
for	O
24	O
hrs	O
The	O
supernatants	O
at	O
24	O
hrs	O
were	O
collected	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
for	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
analysis	O
.	O

NEC	B-DS
enterocyte	O
experiments	O

NEC	B-DS
-	O
IEC	O
were	O
isolated	O
and	O
cultured	O
from	O
the	O
viable	O
margins	O
of	O
resected	O
ileal	O
NEC	B-DS
tissue	O
from	O
a	O
NEC	B-DS
neonate	O
at	O
25	O
-	O
wk	O
gestation	O
[	O
4	O
,	O
11	O
].	O

NEC	B-DS
-	O
IEC	O
were	O
cultured	O
in	O
Opti	O
-	O
Minimal	O
Essential	O
Medium	O
(	O
Opti	O
-	O
MEM	O
)	O
(	O
Gibco	O
Thermofisher	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FBS	O
(	O
Mediatech	O
),	O
0	O
.	O
2	O
U	O
/	O
ml	O
insulin	B-GP
(	O
Eli	O
Lilly	O
and	O
Company	O
),	O
20	O
ng	O
/	O
ml	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
)	O
(	O
EMD	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
),	O
and	O
a	O
1	O
%	O
antibiotic	O
–	O
antimycotic	O
cocktail	O
(	O
Gibco	O
Thermofisher	O
)	O
in	O
a	O
sterile	O
cell	O
culture	O
humidifier	O
at	O
32	O
°	O
C	O
and	O
5	O
%	O
CO2	O
.	O

The	O
cells	O
were	O
incubated	O
with	O
PSA	O
or	O
control	O
PBS	O
media	O
for	O
24	O
hrs	O
and	O
then	O
exposed	O
or	O
not	O
to	O
1ng	O
/	O
ml	O
of	O
recombinant	O
human	B-OG
IL	B-GP
-	I-GP
1β	I-GP
(	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
for	O
24	O
hrs	O
.	O

The	O
supernatants	O
were	O
then	O
collected	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
for	O
a	O
later	O
ELISA	O
analysis	O
.	O

Access	O
to	O
NEC	B-DS
discarded	O
tissue	O
was	O
approved	O
by	O
a	O
Partners	O
IRB	O
(	O
Protocol	O
#:	O
1999P003833	O
/	O
MGH	O
).	O

Fetal	O
mouse	B-OG
model	O

C57BL	O
/	O
6J	O
wild	O
type	O
(	O
WT	O
)	O
mice	B-OG
and	O
TLR4	B-GP
-/-	O
and	O
TLR2	B-GP
-/-	O
mice	B-OG
,	O
both	O
on	O
a	O
C57BL	O
/	O
6J	O
background	O
(	O
Jackson	O
Laboratory	O
),	O
were	O
used	O
.	O

All	O
mice	B-OG
were	O
bred	O
and	O
housed	O
in	O
a	O
specific	O
pathogen	O
free	O
facility	O
.	O

Animals	B-OG
were	O
given	O
water	O
and	O
standard	O
laboratory	O
chow	O
ad	O
libitum	O
.	O

Timed	O
pregnant	O
mice	B-OG
were	O
established	O
by	O
pairing	O
10	O
–	O
12	O
-	O
wk	O
old	O
female	O
mice	B-OG
with	O
proven	O
breeder	O
males	O
just	O
prior	O
to	O
the	O
end	O
of	O
the	O
daily	O
light	O
cycle	O
.	O

The	O
following	O
morning	O
,	O
each	O
female	O
was	O
examined	O
for	O
the	O
presence	O
of	O
an	O
ejaculatory	O
plug	O
in	O
the	O
vagina	O
.	O

When	O
noted	O
,	O
the	O
female	O
was	O
placed	O
in	O
a	O
dated	O
cage	O
and	O
considered	O
pregnant	O
,	O
e	O
.	O
g	O
.,	O
embryonic	O
day	O
(	O
E	O
)	O
0	O
.	O
5	O
.	O

Pups	O
were	O
delivered	O
by	O
caesarean	O
section	O
at	O
E	O
18	O
.	O
5	O
[	O
11	O
].	O

Ileal	O
tissues	O
were	O
then	O
collected	O
for	O
experiments	O
.	O

Animal	B-OG
procedures	O
had	O
been	O
previously	O
approved	O
by	O
the	O
Massachusetts	O
General	O
Hospital	O
Subcommittee	O
on	O
Research	O
Animal	O
Care	O
and	O
Use	O
committee	O
(	O
A3596	O
-	O
01	O
).	O

Fetal	O
mouse	B-OG
ileal	O
organ	O
culture	O

WT	O
,	O
TLR4	B-GP
-/-	O
and	O
TLR2	B-GP
-/-	O
mouse	B-OG
fetal	O
ileal	O
tissues	O
harvested	O
at	O
E	O
18	O
.	O
5	O
were	O
cut	O
into	O
3	O
-	O
mm	O
pieces	O
and	O
maintained	O
in	O
organ	O
culture	O
media	O
as	O
described	O
[	O
11	O
]	O
but	O
also	O
supplemented	O
with	O
an	O
antibiotic	O
-	O
antimycotic	O
cocktail	O
(	O
100	O
unit	O
/	O
ml	O
penicillin	O
,	O
100	O
μg	O
/	O
ml	O
streptomycin	O
and	O
0	O
.	O
25	O
μg	O
/	O
ml	O
fungizone	O
antimycotic	O
)	O
(	O
GibcoThermofisher	O
).	O

After	O
2	O
h	O
at	O
37	O
°	O
C	O
,	O
tissues	O
were	O
pre	O
-	O
treated	O
with	O
and	O
without	O
PSA	O
for	O
24	O
hrs	O
and	O
then	O
stimulated	O
with	O
5ng	O
/	O
ml	O
of	O
recombinant	O
mouse	B-OG
IL	B-GP
-	I-GP
1β	I-GP
(	O
R	O
&	O
D	O
Systems	O
)	O
for	O
24	O
hrs	O
Supernatants	O
were	O
collected	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
for	O
ELISA	O
analysis	O
.	O

ELISA	O

Levels	O
of	O
IL	B-GP
-	I-GP
8	I-GP
were	O
measured	O
in	O
culture	O
supernatants	O
using	O
ELISA	O
kits	O
(	O
R	O
&	O
D	O
system	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

IL	B-GP
-	I-GP
8	I-GP
was	O
quantified	O
in	O
each	O
supernatant	O
in	O
triplicate	O
.	O

Colorimetric	O
results	O
were	O
read	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
.	O

Values	O
were	O
normalized	O
to	O
total	O
protein	O
in	O
cells	O
or	O
organ	O
cultures	O
.	O

Protein	O
was	O
determined	O
by	O
a	O
bicinchoninic	O
acid	O
protein	O
assay	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
modified	O
for	O
96	O
-	O
well	O
microtiter	O
plates	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
protocol	O
.	O

Immunofluorescent	O
staining	O

H4	O
cells	O
cultured	O
on	O
Falcon	O
Culture	O
Slides	O
(	O
Thermofisher	O
)	O
were	O
transfected	O
with	O
human	B-OG
stealth	O
TLR2	B-GP
or	O
TLR4	B-GP
siRNA	O
or	O
control	O
siRNA	O
and	O
then	O
pre	O
-	O
treated	O
with	O
PSA	O
for	O
24	O
hrs	O
as	O
described	O
above	O
and	O
stimulated	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
for	O
2	O
hrs	O
The	O
cells	O
were	O
washed	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
(	O
Gibco	O
Thermofisher	O
)	O
once	O
and	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
for	O
15	O
minutes	O
at	O
room	O
temperature	O
(	O
RT	O
).	O

Cells	O
were	O
washed	O
three	O
times	O
with	O
PBS	O
to	O
remove	O
paraformaldehyde	O
and	O
then	O
blocked	O
in	O
blocking	O
buffer	O
(	O
1xPBS	O
/	O
3	O
%	O
bovine	O
serum	O
albumin	B-GP
/	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
)	O
for	O
60	O
minutes	O
at	O
RT	O
.	O

The	O
cells	O
were	O
then	O
incubated	O
with	O
either	O
anti	O
-	O
phospho	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
(	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
)	O
(	O
1	O
:	O
80	O
)	O
or	O
anti	O
-	O
phospho	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
(	O
P	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
;	O
1	O
:	O
800	O
)	O
in	O
antibody	B-GP
dilution	O
buffer	O
(	O
1xPBS	O
/	O
1	O
%	O
BSA	B-GP
/	O
0	O
.	O
3	O
%	O
Triton	O
X	O
-	O
100	O
)	O
overnight	O
at	O
4	O
°	O
C	O
.	O

After	O
being	O
washed	O
three	O
times	O
with	O
PBS	O
,	O
both	O
were	O
stained	O
with	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
(	O
1	O
:	O
500	O
)	O
at	O
RT	O
for	O
60	O
minutes	O
and	O
washed	O
again	O
with	O
PBS	O
three	O
times	O
.	O

The	O
cell	O
membrane	O
was	O
then	O
stained	O
by	O
anti	O
-	O
phospholipid	O
antibody	B-GP
conjugated	O
with	O
rhodamine	O
(	O
1	O
:	O
500	O
)	O
for	O
1	O
hour	O
at	O
RT	O
.	O

Specimens	O
were	O
then	O
washed	O
three	O
times	O
with	O
PBS	O
,	O
mounted	O
with	O
ProLong	O
Antifade	O
Reagent	O
(	O
Life	O
Technologies	O
)	O
and	O
analyzed	O
with	O
a	O
fluorescent	O
Nikon	O
confocal	O
microscope	O
.	O

The	O
fluorescent	O
intensity	O
was	O
analyzed	O
with	O
Image	O
J	O
(	O
fiji	O
-	O
win64	O
)	O
software	O
.	O

Corrected	O
Total	O
Cell	O
Fluorescence	O
(	O
CTCF	O
)	O
=	O
Integrated	O
Density	O
—(	O
Area	O
of	O
selected	O
cell	O
X	O
the	O
mean	O
fluorescence	O
of	O
background	O
readings	O
)	O
[	O
23	O
]	O
and	O
then	O
calculated	O
.	O

Real	O
-	O
time	O
quantitative	O
reverse	O
transcription	O
PCR	O

The	O
RNA	O
RNeasy	O
Mini	O
kit	O
(	O
Quigen	O
,	O
Valencia	O
,	O
CA	O
)	O
was	O
used	O
for	O
extraction	O
of	O
total	O
RNA	O
from	O
H4	O
cells	O
.	O

RNA	O
was	O
reverse	O
transcribed	O
with	O
random	O
hexamers	O
using	O
an	O
Advantage	O
RT	O
-	O
for	O
–	O
PCR	O
kit	O
(	O
Clontech	O
,	O
Mountain	O
View	O
,	O
CA	O
).	O

The	O
cDNA	O
was	O
amplified	O
using	O
iQ	O
SYBR	O
Green	O
Supermix	O
(	O
Bio	O
-	O
Rad	O
,	O
Philadelphia	O
,	O
PA	O
)	O
and	O
500nM	O
of	O
each	O
primer	O
specified	O
in	O
the	O
next	O
paragraph	O
.	O
β	B-GP
-	I-GP
actin	I-GP
primers	O
were	O
amplified	O
in	O
all	O
samples	O
.	O

Triplicate	O
cDNA	O
samples	O
were	O
amplified	O
with	O
the	O
following	O
primers	O
:	O
Mean	O
threshold	O
cycle	O
(	O
CT	O
)	O
values	O
of	O
each	O
transcript	O
were	O
normalized	O
by	O
subtracting	O
the	O
mean	O
CT	O
value	O
for	O
the	O
β	B-GP
-	I-GP
actin	I-GP
transcript	O
of	O
that	O
sample	O
.	O

The	O
change	O
in	O
the	O
normalized	O
transcript	O
level	O
was	O
expressed	O
relative	O
to	O
the	O
control	O
sample	O
with	O
a	O
change	O
of	O
n	O
in	O
CT	O
representing	O
a	O
2n	O
or	O
greater	O
-	O
fold	O
difference	O
,	O
as	O
described	O
previously	O
[	O
24	O
].	O

Primer	O
sequences	O
used	O
in	O
this	O
study	O
were	O
:	O
Human	B-OG
-	O
TLR2	B-GP
,	O
forward	O
5	O
’-	O
ATCCTCCAATCAGGCTTCTCT	O
-	O
3	O
’,	O
and	O
reverse	O
,	O
5	O
’—	O
GGACAGGTCAAGGCTTTTTACA	O
;	O
Human	B-OG
-	O
TLR4	B-GP
forward	O
,	O
5	O
’-	O
ATGCTGCCGTTTTATCACGGA	O
—	O
3	O
’	O
and	O
reverse	O
,	O
5	O
’-	O
CTAAACTCTGGATGGGGTTTCC	O
–	O
3	O
’,	O
Human	B-OG
-	O
β	B-GP
-	I-GP
actin	I-GP
,	O
forward	O
,	O
5	O
’-	O
CATGTACGTTGCTATCCAGGC	O
-	O
3	O
’,	O
and	O
reverse	O
,	O
5	O
’-	O
CTCCTTAATGTCACGCACGAT	O
-	O
3	O
’	O

Statistical	O
analysis	O
of	O
data	O

Results	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
error	O
of	O
the	O
means	O
(	O
SEM	O
).	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
used	O
to	O
compare	O
the	O
mean	O
of	O
multiple	O
groups	O
.	O

Differences	O
of	O
a	O
P	O
value	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
(*	O
P	O
<	O
0	O
.	O
05	O
,	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
GraphPad	O
Prism	O
6	O
).	O

Results	O

B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
was	O
anti	O
-	O
inflammatory	O
with	O
H4	O
cells	O

In	O
order	O
to	O
determine	O
the	O
effect	O
of	O
PSA	O
expressed	O
on	O
the	O
surface	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
on	O
anti	O
-	O
inflammation	O
after	O
IL	B-GP
-	I-GP
1β	I-GP
stimulus	O
,	O
H4	O
cells	O
were	O
incubated	O
with	O
either	O
wild	O
type	O
B	B-OG
.	I-OG
fragilis	I-OG
(	O
PSA	O
dossa	O
)	O
or	O
mutant	O
B	B-OG
.	I-OG
fragilis	I-OG
(	O
PSA	O
delta	O
)	O
followed	O
by	O
an	O
inflammatory	O
stimulus	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
or	O
not	O
.	O

Only	O
B	B-OG
.	I-OG
fragilis	I-OG
expressing	O
PSA	O
on	O
its	O
surface	O
resulted	O
in	O
a	O
reduction	O
in	O
the	O
IL	B-GP
-	I-GP
8	I-GP
response	O
(	O
Fig	O
1	O
)	O

Wild	O
type	O
(	O
WT	O
)	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
polysaccharides	O
A	O
(	O
PSA	O
dossa	O
)	O
reduced	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
triggered	O
IL8	B-GP
in	O
immature	O
human	B-OG
fetal	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
H4	O
cells	O
).	O

H4	O
cells	O
were	O
pretreated	O
with	O
WT	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
(	O
dossa	O
)	O
or	O
mutant	O
type	O
without	O
PSA	O
(	O
delta	O
)	O
at	O
an	O
indicated	O
dosage	O
for	O
1	O
hour	O
.	O

Then	O
the	O
cells	O
were	O
stimulated	O
with	O
or	O
without	O
IL	B-GP
-	I-GP
1β	I-GP
for	O
24	O
hrs	O
.	O

The	O
supernatant	O
IL8	B-GP
levels	O
were	O
determined	O
by	O
Elisa	O
.	O

Data	O
are	O
represented	O
as	O
mean	O
±	O
SD	O
(	O
n	O
=	O
3	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

Three	O
experiments	O
with	O
similar	O
results	O
were	O
analyzed	O
.	O

Purified	O
PSA	O
was	O
anti	O
-	O
inflammatory	O
with	O
H4	O
cells	O

We	O
next	O
used	O
purified	O
PSA	O
exposed	O
to	O
H4	O
cells	O
to	O
begin	O
to	O
define	O
the	O
anti	O
-	O
inflammatory	O
effect	O
.	O

When	O
purified	O
PSA	O
was	O
exposed	O
to	O
H4	O
cells	O
at	O
the	O
optimal	O
dose	O
,	O
based	O
on	O
a	O
dose	O
response	O
curve	O
,	O
before	O
an	O
IL	B-GP
-	I-GP
1β	I-GP
inflammatory	O
stimulus	O
or	O
not	O
.	O

IL	B-GP
-	I-GP
8	I-GP
was	O
significantly	O
reduced	O
compared	O
to	O
controls	O
(	O
Fig	O
2	O
).	O

PSA	O
reduced	O
IL	B-GP
-	I-GP
1βinduced	I-GP
IL	B-GP
-	I-GP
8	I-GP
in	O
H4	O
cells	O
.	O

H4	O
cells	O
were	O
pretreated	O
with	O
or	O
without	O
PSA	O
at	O
an	O
optimal	O
dose	O
and	O
then	O
exposed	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
or	O
treated	O
with	O
PSA	O
alone	O
.	O

The	O
supernatants	O
were	O
collected	O
to	O
measure	O
IL8	B-GP
levels	O
by	O
Elisa	O
.	O

The	O
mean	O
and	O
SEM	O
were	O
from	O
triplicate	O
wells	O
and	O
were	O
representative	O
of	O
three	O
separate	O
experiments	O
with	O
similar	O
results	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
(	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

PSA	O
is	O
anti	O
-	O
inflammatory	O
in	O
fetal	O
enterocytes	O
from	O
resected	O
NEC	B-DS
small	O
intestine	O
(	O
NEC	B-DS
-	O
IEC	O
)	O

In	O
order	O
to	O
confirm	O
that	O
the	O
B	B-OG
.	I-OG
fragilis	I-OG
-	O
PSA	O
effect	O
also	O
existed	O
in	O
a	O
primary	O
cell	O
line	O
isolated	O
from	O
the	O
resected	O
small	O
intestine	O
of	O
a	O
NEC	B-DS
patient	O
at	O
surgery	O
,	O
NEC	B-DS
-	O
IECs	O
were	O
incubated	O
with	O
PSA	O
and	O
then	O
stimulated	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

As	O
with	O
H4	O
cells	O
,	O
PSA	O
was	O
anti	O
-	O
inflammatory	O
in	O
NEC	B-DS
-	O
IECs	O
(	O
Fig	O
3	O
).	O

PSA	O
reduced	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
triggered	O
IL	B-GP
-	I-GP
8	I-GP
in	O
necrotizing	B-DS
enterocolitis	I-DS
intestinal	O
epithelial	O
cells	O
(	O
NEC	B-DS
-	O
IEC	O
).	O

NEC	B-DS
-	O
IEC	O
cells	O
were	O
pretreated	O
with	O
or	O
without	O
PSA	O
and	O
then	O
exposed	O
to	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
for	O
24	O
hrs	O
or	O
treated	O
with	O
PSA	O
alone	O
.	O

The	O
supernatant	O
IL8	B-GP
levels	O
induced	O
by	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
were	O
reduced	O
by	O
PSA	O
pretreatment	O
.	O

The	O
mean	O
and	O
SEM	O
were	O
from	O
triplicate	O
wells	O
and	O
were	O
representative	O
of	O
three	O
separate	O
experiments	O
with	O
similar	O
results	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
(	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

The	O
PSA	O
effect	O
on	O
H4	O
cells	O
is	O
TLR2	B-GP
and	O
TLR4	B-GP
dependent	O

Having	O
previously	O
shown	O
that	O
“	O
pioneer	O
”	O
bacterial	O
secretions	O
anti	O
-	O
inflammatory	O
effect	O
was	O
TLR4	B-GP
dependent	O
and	O
that	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
mediated	O
anti	O
-	O
inflammation	O
in	O
dendritic	O
/	O
lymphoid	O
cells	O
,	O
we	O
begin	O
to	O
determine	O
the	O
mechanism	O
of	O
the	O
PSA	O
effect	O
on	O
H4	O
cells	O
,	O
TLR2	B-GP
and	O
TLR4	B-GP
molecules	O
were	O
knocked	O
down	O
.	O

Control	O
cells	O
and	O
knocked	O
down	O
cells	O
were	O
exposed	O
to	O
PSA	O
before	O
IL	B-GP
-	I-GP
1β	I-GP
inflammatory	O
stimulus	O
.	O

An	O
anti	O
-	O
inflammatory	O
effect	O
was	O
only	O
noted	O
in	O
control	O
H4	O
cells	O
and	O
not	O
in	O
TLR2	B-GP
or	O
TLR4	B-GP
knocked	O
down	O
cells	O
.	O

(	O
Fig	O
4	O
).	O

Both	O
TLR4	B-GP
and	O
TLR2	B-GP
are	O
required	O
for	O
PSA	O
prevention	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
induced	O
IL8	B-GP
in	O
H4	O
cells	O
.	O

Control	O
(	O
A	O
)	O
and	O
TLR2	B-GP
(	O
B	O
)	O
or	O
TLR4	B-GP
(	O
C	O
)	O
knockdown	O
H4	O
cells	O
were	O
pretreated	O
with	O
or	O
without	O
PSA	O
and	O
then	O
exposed	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
for	O
24	O
hrs	O
or	O
treated	O
with	O
PSA	O
alone	O
.	O

The	O
supernatants	O
were	O
collected	O
to	O
measure	O
IL8	B-GP
levels	O
by	O
Elisa	O
.	O

The	O
mean	O
and	O
SEM	O
were	O
from	O
triplicate	O
wells	O
and	O
were	O
representative	O
of	O
three	O
separate	O
experiments	O
with	O
similar	O
results	O
***	O
P	O
<	O
0	O
.	O
001	O
(	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

PSA	O
was	O
not	O
anti	O
-	O
inflammatory	O
in	O
TLR2	B-GP
and	O
TLR4	B-GP
knockout	O
fetal	O
mouse	B-OG
small	O
intestinal	O
organ	O
culture	O

To	O
confirm	O
the	O
in	O
vitro	O
observation	O
that	O
TLR2	B-GP
and	O
TLR4	B-GP
were	O
involved	O
in	O
anti	O
-	O
inflammation	O
in	O
H4	O
cells	O
,	O
in	O
vivo	O
TLR2	B-GP
-/-	O
and	O
TLR4	B-GP
-/-	O
mice	B-OG
were	O
used	O
in	O
organ	O
culture	O
to	O
determine	O
the	O
PSA	O
effect	O
an	O
IL	B-GP
-	I-GP
1β	I-GP
inflammatory	O
stimulus	O
.	O

TLR2	B-GP
and	O
TLR4	B-GP
knockout	O
fetal	O
mice	B-OG
were	O
exposed	O
to	O
PSA	O
and	O
stimulated	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

As	O
with	O
H4	O
cells	O
,	O
PSA	O
was	O
anti	O
-	O
inflammatory	O
in	O
control	O
but	O
not	O
TLR2	B-GP
or	O
TLR4	B-GP
knockout	O
mice	B-OG
(	O
Fig	O
5	O
).	O

TLR4	B-GP
and	O
TLR2	B-GP
are	O
required	O
for	O
PSA	O
reduction	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
IL8	B-GP
in	O
fetal	O
mouse	B-OG
small	O
intestinal	O
organ	O
cultures	O
.	O

Embryonic	O
18	O
.	O
5	O
day	O
(	O
E18	O
.	O
5	O
)	O
mouse	B-OG
fetal	O
small	O
intestinal	O
organ	O
culture	O
were	O
pretreated	O
with	O
or	O
without	O
PSA	O
in	O
(	O
A	O
)	O
wild	O
type	O
(	O
WT	O
),	O
(	O
B	O
)	O
TLR2	B-GP
-/-	O
and	O
(	O
C	O
)	O
TLR4	B-GP
-/-	O
mice	B-OG
.	O

The	O
supernatant	O
IL8	B-GP
levels	O
were	O
detected	O
24	O
hrs	O
after	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
stimulation	O
.	O

The	O
mean	O
and	O
SEM	O
were	O
from	O
triplicate	O
wells	O
and	O
were	O
representative	O
of	O
three	O
separate	O
experiments	O
with	O
similar	O
results	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
(	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

PSA	O
was	O
effective	O
in	O
reducing	O
IL	B-GP
-	I-GP
1β	I-GP
induced	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
expression	O
in	O
control	O
and	O
TLR4	B-GP
knockdown	O
but	O
not	O
TLR2	B-GP
knockdown	O
H4	O
cells	O

To	O
determine	O
if	O
AP1	B-GP
transcription	B-GP
factor	I-GP
activation	O
by	O
IL	B-GP
-	I-GP
1β	I-GP
occurred	O
and	O
TLR2	B-GP
or	O
TLR4	B-GP
knocked	O
down	O
H4	O
cells	O
was	O
involved	O
after	O
PSA	O
exposure	O
(	O
Fig	O
6	O
),	O
control	O
siRNA	O
(	O
Fig	O
6A1	O
and	O
6A2	O
),	O
TLR2	B-GP
siRNA	O
(	O
Fig	O
6B1	O
and	O
6B2	O
)	O
and	O
TLR4	B-GP
siRNA	O
(	O
Fig	O
6C1	O
and	O
6C2	O
)	O
transfected	O
cells	O
were	O
exposed	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
with	O
and	O
without	O
PSA	O
pretreatment	O
and	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
staining	O
was	O
determined	O
.	O

The	O
results	O
showed	O
that	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
was	O
increased	O
significantly	O
after	O
IL	B-GP
-	I-GP
1β	I-GP
stimulation	O
and	O
that	O
PSA	O
reduced	O
the	O
response	O
in	O
control	O
siRNA	O
treated	O
and	O
TLR4	B-GP
knocked	O
down	O
siRNA	O
but	O
not	O
in	O
TLR2	B-GP
knockdown	O
cells	O
.	O

The	O
same	O
results	O
were	O
noted	O
for	O
the	O
P	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
gene	O
(	O
data	O
not	O
shown	O
).	O

These	O
results	O
suggest	O
that	O
after	O
TLR2	B-GP
knockdown	O
,	O
the	O
transcription	B-GP
factor	I-GP
genes	O
(	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
)	O
were	O
activated	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

The	O
response	O
was	O
inhibited	O
after	O
PSA	O
exposure	O
in	O
part	O
due	O
to	O
TLR2	B-GP
but	O
not	O
TLR4	B-GP
dependence	O
.	O

PSA	O
reduced	O
IL	B-GP
-	I-GP
1β	I-GP
induced	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
expression	O
is	O
TLR2	B-GP
dependent	O
.	O

P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
(	O
green	O
color	O
)	O
was	O
detected	O
by	O
immunofluorescent	O
staining	O
in	O
control	O
(	O
A1	O
),	O
TLR2	B-GP
knockdown	O
(	O
B1	O
)	O
and	O
TLR4	B-GP
knockdown	O
(	O
C1	O
)	O
H4	O
cells	O
which	O
were	O
pretreated	O
with	O
or	O
without	O
PSA	O
for	O
24	O
hrs	O
and	O
then	O
exposed	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
for	O
2	O
hrs	O
The	O
nuclei	O
were	O
counterstained	O
by	O
Dapi	O
(	O
blue	O
),	O
and	O
the	O
cell	O
membrane	O
was	O
stained	O
red	O
.	O

Amplified	O
x600	O
;	O
scale	O
bar	O
=	O
20	O
μm	O
;	O
n	O
=	O
60	O
–	O
70	O
cells	O
/	O
treatment	O
.	O

The	O
images	O
were	O
representative	O
of	O
three	O
separate	O
experiments	O
with	O
similar	O
results	O
.	O

The	O
analysis	O
(	O
A2	O
,	O
B2	O
and	O
C2	O
)	O
applied	O
by	O
corrected	O
total	O
cell	O
fluorescence	O
(	O
CTCF	O
)	O
was	O
determined	O
.**	O
P	O
<	O
0	O
.	O
01	O
,	O
***	O
P	O
<	O
0	O
.	O
001	O
(	O
one	O
-	O
way	O
ANOVA	O
and	O
post	O
-	O
hoc	O
tests	O
).	O

Discussion	O

This	O
laboratory	O
has	O
had	O
a	O
long	O
standing	O
interest	O
in	O
the	O
interaction	O
between	O
colonizing	O
bacteria	B-OG
and	O
the	O
developing	O
human	B-OG
intestine	O
.	O

We	O
have	O
shown	O
that	O
colonizing	O
bacteria	B-OG
interacting	O
with	O
the	O
premature	O
human	B-OG
intestine	O
preferentially	O
stimulates	O
inflammation	O
over	O
immune	O
homeostasis	O
[	O
1	O
,	O
2	O
,	O
8	O
].	O

We	O
have	O
also	O
reported	O
that	O
the	O
stimulation	O
by	O
certain	O
bacteria	B-OG
can	O
mediate	O
excessive	O
inflammation	O
through	O
activation	O
of	O
immature	O
innate	O
immune	B-GP
inflammatory	I-GP
response	I-GP
genes	I-GP
in	O
fetal	O
enterocytes	O
[	O
8	O
,	O
11	O
].	O

Yet	O
,	O
there	O
are	O
also	O
clinical	O
and	O
experimental	O
evidence	O
to	O
suggest	O
that	O
probiotics	O
and	O
their	O
secretions	O
may	O
also	O
have	O
a	O
protective	O
effect	O
against	O
this	O
enhanced	O
inflammatory	O
response	O
[	O
6	O
,	O
25	O
]	O
suggesting	O
a	O
paradoxical	O
situation	O
.	O

This	O
observation	O
may	O
be	O
important	O
clinically	O
.	O

A	O
major	O
intestinal	O
inflammatory	O
condition	O
,	O
necrotizing	B-DS
enterocolitis	I-DS
(	O
NEC	B-DS
),	O
occurs	O
commonly	O
in	O
premature	O
infants	O
less	O
than	O
1500	O
gms	O
[	O
3	O
,	O
10	O
].	O

NEC	B-DS
is	O
associated	O
with	O
multiple	O
risk	O
factors	O
after	O
premature	O
birth	O
including	O
hypoxic	O
-	O
ischemic	O
events	O
,	O
the	O
use	O
of	O
formula	O
feeding	O
,	O
and	O
a	O
dysbiotic	O
bacterial	O
colonization	O
resulting	O
in	O
an	O
increased	O
likelihood	O
of	O
severe	O
intestinal	O
inflammation	O
,	O
coagulation	O
necrosis	O
and	O
gastrointestinal	O
bleeding	O
[	O
3	O
,	O
5	O
,	O
12	O
].	O

We	O
believe	O
that	O
a	O
major	O
pathogenic	O
mechanism	O
of	O
NEC	B-DS
is	O
the	O
accentuated	O
response	O
of	O
the	O
immature	O
intestine	O
to	O
colonizing	O
bacteria	B-OG
.	O

Yet	O
paradoxically	O
a	O
major	O
probiotic	O
which	O
has	O
been	O
shown	O
clinically	O
to	O
protect	O
against	O
the	O
expression	O
of	O
NEC	B-DS
is	O
Bifidobacterium	B-OG
longum	I-OG
subsp	I-OG
infantis	I-OG
[	O
4	O
,	O
8	O
,	O
25	O
].	O

Accordingly	O
,	O
we	O
have	O
carefully	O
studied	O
the	O
mechanism	O
by	O
which	O
this	O
probiotic	O
and	O
its	O
secretions	O
alter	O
enterocyte	O
inflammation	O
in	O
the	O
immature	O
human	B-OG
intestine	O
.	O

In	O
that	O
study	O
,	O
we	O
focused	O
on	O
the	O
effect	O
of	O
B	B-OG
.	I-OG
infantis	I-OG
secretions	O
on	O
the	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
inflammatory	O
response	O
in	O
premature	O
human	B-OG
enterocytes	O
.	O

IL	B-GP
-	I-GP
1β	I-GP
is	O
an	O
important	O
inflammatory	B-GP
cytokine	I-GP
associated	O
with	O
the	O
pathogenesis	O
of	O
NEC	B-DS
and	O
functions	O
by	O
mediating	O
inflammatory	O
cell	O
recruitment	O
and	O
amplifying	O
the	O
innate	O
immune	O
response	O
via	O
enterocyte	O
signaling	O
[	O
26	O
,	O
27	O
].	O

The	O
gut	O
is	O
colonized	O
with	O
trillions	O
of	O
beneficial	O
commensal	B-OG
microorganisms	I-OG
which	O
normally	O
maintain	O
a	O
mutually	O
beneficial	O
symbiotic	O
relationship	O
with	O
the	O
host	O
.	O

To	O
maintain	O
intestinal	O
homeostasis	O
,	O
both	O
IEC	O
and	O
gut	O
associated	O
immune	O
cells	O
recognize	O
bacterial	O
components	O
via	O
pattern	B-GP
recognition	I-GP
receptors	I-GP
(	O
PRRs	B-GP
)	O
to	O
conserve	O
a	O
balance	O
between	O
tolerance	O
to	O
the	O
large	O
communities	O
of	O
resident	O
luminal	O
bacteria	B-OG
while	O
at	O
the	O
same	O
time	O
being	O
able	O
to	O
mount	O
an	O
inflammatory	O
response	O
against	O
pathogens	O
[	O
28	O
].	O

TLRs	B-GP
are	O
a	O
major	O
class	O
of	O
PRRs	B-GP
that	O
are	O
present	O
on	O
IECs	O
and	O
mucosal	O
immune	O
cells	O
which	O
are	O
involved	O
in	O
the	O
induction	O
of	O
both	O
tolerance	O
and	O
inflammation	O
[	O
29	O
,	O
30	O
].	O

TLR2	B-GP
and	O
TLR4	B-GP
are	O
two	O
of	O
10	O
or	O
more	O
members	O
of	O
the	O
TLR	B-GP
family	O
.	O

In	O
recent	O
studies	O
with	O
B	B-OG
.	I-OG
fragilis	I-OG
expressing	O
PSA	O
and	O
with	O
PSA	O
alone	O
,	O
TLR2	B-GP
had	O
been	O
implicated	O
in	O
the	O
interaction	O
with	O
CD4	B-GP
lymphocytes	O
and	O
dendritic	O
cells	O
[	O
16	O
,	O
17	O
].	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
has	O
been	O
identified	O
during	O
the	O
first	O
week	O
of	O
life	O
in	O
intestinal	O
contents	O
of	O
full	O
term	O
,	O
vaginally	O
delivered	O
human	B-OG
infants	O
,	O
particularly	O
when	O
the	O
infant	O
was	O
exclusively	O
breast	O
fed	O
[	O
13	O
].	O

This	O
study	O
is	O
an	O
initial	O
in	O
vitro	O
attempt	O
to	O
identify	O
with	O
another	O
so	O
called	O
“	O
pioneer	O
”	O
colonizing	O
bacterium	B-OG
,	O
B	B-OG
.	I-OG
fragilis	I-OG
,	O
if	O
additional	O
anti	O
-	O
inflammatory	O
effects	O
occur	O
in	O
a	O
fetal	O
intestinal	O
cell	O
line	O
after	O
inflammatory	O
stimulus	O
.	O

This	O
so	O
called	O
“	O
pioneer	O
”	O
microorganism	B-OG
has	O
been	O
implicated	O
in	O
reducing	O
the	O
tendency	O
for	O
intestinal	O
inflammation	O
in	O
infant	O
intestine	O
in	O
the	O
first	O
month	O
of	O
life	O
[	O
4	O
].	O

Experimentally	O
,	O
B	B-OG
.	I-OG
fragilis	I-OG
containing	O
PSA	O
and	O
PSA	O
alone	O
when	O
given	O
to	O
germ	O
free	O
mouse	B-OG
models	O
stimulate	O
a	O
balance	O
between	O
TH1	O
and	O
TH2	O
CD4	B-GP
lymphocytes	O
,	O
a	O
step	O
thought	O
to	O
be	O
necessary	O
in	O
developing	O
of	O
immune	O
homeostasis	O
and	O
preventing	O
the	O
increased	O
expression	O
of	O
allergic	B-DS
disease	I-DS
seen	O
in	O
developed	O
countries	O
[	O
31	O
].	O

TLR2	B-GP
has	O
been	O
specifically	O
implicated	O
in	O
the	O
stimulation	O
of	O
FOXP3	B-GP
+	O
Tregs	O
cells	O
to	O
produce	O
IL	B-GP
-	I-GP
10	I-GP
which	O
leads	O
to	O
the	O
suppression	O
of	O
the	O
release	O
of	O
IL	B-GP
-	I-GP
17	I-GP
cytokines	B-GP
implemented	O
in	O
intestinal	O
inflammation	O
[	O
16	O
].	O

In	O
recent	O
studies	O
,	O
we	O
have	O
shown	O
that	O
secretions	O
from	O
Bifidobacteria	B-OG
infantis	I-OG
,	O
another	O
“	O
pioneer	O
”	O
bacteria	B-OG
,	O
can	O
mediate	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
anti	O
-	O
inflammation	O
in	O
fetal	O
intestine	O
via	O
the	O
TLR4	B-GP
receptor	I-GP
[	O
11	O
],	O
suggesting	O
that	O
increased	O
expression	O
of	O
TLR2	B-GP
and	O
TLR4	B-GP
on	O
the	O
immature	O
intestinal	O
surface	O
may	O
help	O
to	O
mediate	O
anti	O
-	O
inflammation	O
from	O
these	O
“	O
pioneer	O
”	O
neonatal	O
bacteria	B-OG
.	O

However	O
,	O
no	O
studies	O
have	O
been	O
done	O
to	O
determine	O
the	O
role	O
of	O
the	O
“	O
pioneer	O
”	O
expressed	O
microorganism	B-OG
Bacteroides	B-OG
fragilis	I-OG
in	O
preventing	O
excessive	O
enterocyte	O
inflammation	O
in	O
human	B-OG
immature	O
intestine	O
.	O

Accordingly	O
,	O
using	O
established	O
ex	O
vivo	O
human	B-OG
fetal	O
intestinal	O
models	O
developed	O
in	O
this	O
laboratory	O
,	O
we	O
started	O
to	O
determine	O
the	O
effect	O
of	O
PSA	O
on	O
Bacteroides	B-OG
fragilis	I-OG
an	O
initial	O
in	O
vitro	O
study	O
using	O
a	O
fetal	O
intestinal	O
primary	O
cell	O
line	O
and	O
primary	O
enterocytes	O
isolated	O
from	O
NEC	B-DS
intestinal	O
resection	O
.	O

We	O
have	O
previously	O
reported	O
that	O
fetal	O
human	B-OG
intestine	O
favors	O
excessive	O
inflammation	O
over	O
anti	O
-	O
inflammation	O
[	O
8	O
].	O

We	O
have	O
also	O
reported	O
that	O
conventional	O
commensal	B-OG
bacteria	I-OG
can	O
trigger	O
intestinal	O
inflammation	O
in	O
fetal	O
but	O
not	O
mature	O
intestinal	O
enterocytes	O
,	O
presumably	O
due	O
to	O
expression	O
of	O
immature	O
innate	O
immune	B-GP
inflammatory	I-GP
response	I-GP
genes	I-GP
[	O
32	O
].	O

Yet	O
premature	O
infants	O
can	O
be	O
protected	O
from	O
the	O
severe	O
intestinal	O
inflammation	O
of	O
NEC	B-DS
by	O
commensals	O
acting	O
as	O
probiotics	O
[	O
6	O
,	O
7	O
,	O
25	O
].	O

This	O
paradoxical	O
response	O
to	O
colonizing	O
bacteria	B-OG
by	O
fetal	O
intestine	O
was	O
recently	O
underscored	O
by	O
our	O
published	O
observation	O
that	O
secretions	O
from	O
another	O
“	O
pioneer	O
”	O
bacterium	B-OG
(	O
Bacteroides	B-OG
infantis	I-OG
)	O
can	O
reduce	O
intestinal	O
inflammation	O
after	O
an	O
IL	B-GP
-	I-GP
1β	I-GP
inflammatory	O
stimulus	O
.	O

Furthermore	O
,	O
as	O
stated	O
this	O
anti	O
-	O
inflammatory	O
response	O
by	O
B	B-OG
.	I-OG
infantis	I-OG
secretions	O
is	O
mediated	O
through	O
the	O
TLR4	B-GP
receptor	I-GP
[	O
11	O
].	O

This	O
observation	O
represents	O
an	O
unconventional	O
function	O
for	O
the	O
TLR4	B-GP
receptor	I-GP
and	O
suggests	O
that	O
toll	B-GP
receptors	I-GP
in	O
the	O
immature	O
intestine	O
may	O
exhibit	O
different	O
functions	O
.	O

Accordingly	O
,	O
since	O
the	O
TLR2	B-GP
receptor	I-GP
has	O
been	O
implicated	O
in	O
the	O
function	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
and	O
the	O
development	O
of	O
immune	O
homeostasis	O
,	O
particularly	O
anti	O
-	O
inflammation	O
of	O
lymphocyte	O
cells	O
during	O
the	O
newborn	O
period	O
and	O
B	B-OG
.	I-OG
infantis	I-OG
mediates	O
anti	O
-	O
inflammation	O
through	O
the	O
TLR4	B-GP
receptor	I-GP
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
in	O
excessive	O
inflammation	O
by	O
fetal	O
human	B-OG
enterocytes	O
and	O
have	O
begun	O
to	O
determine	O
the	O
role	O
of	O
TLR2	B-GP
and	O
TLR4in	O
this	O
process	O
.	O

Therefore	O
,	O
we	O
have	O
used	O
a	O
human	B-OG
fetal	O
small	O
intestinal	O
epithelial	O
cell	O
line	O
(	O
H4	O
cells	O
)	O
and	O
knocked	O
down	O
its	O
TLR2	B-GP
and	O
TLR4	B-GP
genes	O
.	O

The	O
cells	O
were	O
then	O
pretreated	O
with	O
or	O
without	O
PSA	O
and	O
stimulated	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
before	O
measuring	O
IL	B-GP
-	I-GP
8	I-GP
.	O

The	O
results	O
showed	O
that	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
and	O
PSA	O
alone	O
prevented	O
IL	B-GP
-	I-GP
8	I-GP
induction	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
in	O
control	O
but	O
not	O
in	O
TLR2	B-GP
and	O
TLR4	B-GP
gene	O
knockdown	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
both	O
TLR2	B-GP
and	O
TLR4	B-GP
are	O
participants	O
in	O
the	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
effect	O
in	O
the	O
prevention	O
of	O
the	O
IL	B-GP
-	I-GP
8	I-GP
inflammatory	O
response	O
in	O
immature	O
H4	O
cells	O
.	O

We	O
have	O
demonstrated	O
a	O
similar	O
PSA	O
anti	O
-	O
inflammatory	O
effect	O
in	O
NEC	B-DS
-	O
IEC	O
.	O

To	O
confirm	O
these	O
results	O
,	O
we	O
extended	O
these	O
observations	O
to	O
an	O
in	O
vivo	O
fetal	O
mouse	B-OG
model	O
by	O
applying	O
similar	O
conditions	O
to	O
embryo	O
18	O
.	O
5	O
day	O
(	O
E	O
18	O
.	O
5	O
)	O
fetal	O
small	O
intestinal	O
organ	O
cultures	O
[	O
11	O
]	O
from	O
control	O
,	O
TLR4	B-GP
-/-	O
and	O
TLR2	B-GP
-/-	O
mouse	B-OG
strains	O
.	O

PSA	O
attenuated	O
IL	B-GP
-	I-GP
8	I-GP
induction	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
in	O
control	O
but	O
not	O
in	O
TLR2	B-GP
-/-	O
and	O
TLR4	B-GP
-/-	O
mice	B-OG
.	O

These	O
results	O
suggest	O
that	O
PSA	O
requires	O
both	O
the	O
TLR2	B-GP
and	O
TLR4	B-GP
receptors	I-GP
to	O
prevent	O
or	O
attenuate	O
IL	B-GP
-	I-GP
1β	I-GP
—	O
induced	O
IL	B-GP
-	I-GP
8	I-GP
activation	O
.	O

Although	O
the	O
underlying	O
mechanism	O
for	O
anti	O
-	O
inflammation	O
via	O
both	O
TLR2	B-GP
and	O
TLR4	B-GP
is	O
not	O
known	O
,	O
we	O
do	O
know	O
that	O
PSA	O
is	O
a	O
zwitterion	O
with	O
both	O
positive	O
and	O
negative	O
charges	O
expressed	O
on	O
the	O
molecule	O
[	O
20	O
,	O
33	O
].	O

We	O
also	O
know	O
that	O
TLR2	B-GP
and	O
TLR4	B-GP
can	O
interact	O
with	O
both	O
positive	O
and	O
negative	O
charged	O
molecules	O
[	O
34	O
,	O
35	O
].	O

Accordingly	O
,	O
electrostatic	O
interaction	O
with	O
surface	O
molecules	O
,	O
e	O
.	O
g	O
.,	O
TLRs	B-GP
on	O
the	O
fetal	O
enterocyte	O
may	O
contribute	O
to	O
a	O
decrease	O
in	O
signals	O
that	O
mediate	O
the	O
IL	B-GP
-	I-GP
8	I-GP
response	O
.	O

Further	O
studies	O
are	O
needed	O
however	O
to	O
establish	O
the	O
actual	O
mechanism	O
,	O
particularly	O
for	O
the	O
TLR4	B-GP
receptor	I-GP
.	O

We	O
have	O
previously	O
reported	O
that	O
AP	B-GP
-	I-GP
1	I-GP
is	O
a	O
specific	O
nuclear	B-GP
transcriptional	I-GP
factor	I-GP
for	O
IL	B-GP
-	I-GP
1β	I-GP
induced	O
IL	B-GP
-	I-GP
6	I-GP
/	O
IL	B-GP
-	I-GP
8	I-GP
secretions	O
,	O
but	O
only	O
in	O
immature	O
enterocytes	O
[	O
36	O
].	O

AP	B-GP
-	I-GP
1	I-GP
is	O
composed	O
of	O
c	B-GP
-	I-GP
Jun	I-GP
and	O
c	B-GP
-	I-GP
Fos	I-GP
genes	O
which	O
are	O
phosphorylated	O
in	O
their	O
active	O
form	O
.	O

To	O
investigate	O
the	O
role	O
of	O
AP	B-GP
-	I-GP
1	I-GP
in	O
probiotic	O
prevention	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
induced	O
IL	B-GP
-	I-GP
8	I-GP
in	O
H4	O
cells	O
,	O
we	O
used	O
TLR2	B-GP
and	O
TLR4	B-GP
gene	O
knocked	O
down	O
cells	O
and	O
pretreated	O
these	O
cells	O
with	O
or	O
without	O
PSA	O
before	O
stimulation	O
with	O
IL	B-GP
-	I-GP
1β	I-GP
.	O

Immunofluorescent	O
staining	O
was	O
used	O
to	O
determine	O
phospho	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
(	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
)	O
and	O
phospho	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
(	O
P	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
)	O
(	O
data	O
not	O
shown	O
).	O

In	O
this	O
study	O
,	O
PSA	O
exposure	O
prevented	O
both	O
the	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
and	O
P	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
increase	O
in	O
WT	O
and	O
TLR4	B-GP
knockdown	O
cells	O
but	O
not	O
in	O
TLR2	B-GP
knockdown	O
cells	O
.	O

These	O
observations	O
suggested	O
that	O
in	O
immature	O
enterocytes	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
and	O
PSA	O
alone	O
prevent	O
IL	B-GP
-	I-GP
1β	I-GP
signaling	O
in	O
TLR2	B-GP
knockdown	O
but	O
not	O
TLR4	B-GP
knockdown	O
at	O
least	O
in	O
part	O
through	O
AP	B-GP
-	I-GP
1	I-GP
genes	O
.	O

Although	O
TLR4	B-GP
is	O
involved	O
in	O
anti	O
-	O
inflammation	O
it	O
functions	O
in	O
immature	O
enterocytes	O
by	O
as	O
yet	O
to	O
be	O
determined	O
additional	O
mechanisms	O
.	O

We	O
plan	O
to	O
examine	O
transcription	B-GP
factors	I-GP
of	O
PSA	O
interaction	O
with	O
H4	O
cell	O
RNA	O
to	O
determine	O
possible	O
additional	O
pathways	O
for	O
TLR4	B-GP
involvement	O
in	O
PSA	O
-	O
mediated	O
anti	O
-	O
inflammation	O
in	O
fetal	O
and	O
NEC	B-DS
enterocytes	O
.	O

Conclusions	O

This	O
study	O
shows	O
for	O
the	O
first	O
time	O
that	O
Bacteroides	B-OG
fragilis	I-OG
with	O
PSA	O
and	O
PSA	O
alone	O
has	O
an	O
anti	O
-	O
inflammatory	O
effect	O
on	O
IL	B-GP
-	I-GP
1β	I-GP
stimulation	O
of	O
IL	B-GP
-	I-GP
8	I-GP
in	O
fetal	O
human	B-OG
enterocytes	O
,	O
NEC	B-DS
enterocytes	O
and	O
fetal	O
mouse	B-OG
small	O
intestine	O
.	O

This	O
anti	O
-	O
inflammation	O
is	O
both	O
TLR2	B-GP
and	O
TLR4	B-GP
dependent	O
and	O
mediated	O
in	O
part	O
through	O
a	O
down	O
regulation	O
of	O
P	O
-	O
c	B-GP
-	I-GP
Jun	I-GP
and	O
P	O
-	O
c	B-GP
-	I-GP
Fos	I-GP
of	O
the	O
AP1	B-GP
(	O
TLR2	B-GP
response	O
),	O
a	O
developmentally	O
-	O
regulated	O
transcription	B-GP
factor	I-GP
.	O

This	O
in	O
vitro	O
study	O
represents	O
an	O
initial	O
step	O
in	O
defining	O
the	O
role	O
of	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
in	O
anti	O
-	O
inflammation	O
in	O
the	O
premature	O
intestine	O
.	O

Before	O
recommendations	O
can	O
be	O
made	O
for	O
clinical	O
use	O
of	O
this	O
“	O
pioneer	O
”	O
bacterium	B-OG
,	O
the	O
observation	O
needs	O
to	O
be	O
repeated	O
in	O
a	O
mouse	B-OG
NEC	B-DS
model	O
and	O
decreased	O
inflammation	O
demonstrated	O
after	O
B	B-OG
.	I-OG
fragilis	I-OG
PSA	O
and	O
mutant	O
non	O
PSA	O
(	O
not	O
demonstrated	O
)	O
strands	O
have	O
been	O
studied	O
.	O

In	O
addition	O
,	O
we	O
plan	O
to	O
confirm	O
these	O
results	O
of	O
this	O
organism	O
’	O
s	O
effect	O
in	O
TLR2	B-GP
-/-	O
and	O
TLR4	B-GP
-/-	O
premature	O
neonates	O
.	O

Since	O
B	B-OG
.	I-OG
fragilis	I-OG
with	O
PSA	O
is	O
a	O
“	O
pioneer	O
”	O
bacterium	B-OG
seen	O
in	O
the	O
neonatal	O
intestine	O
,	O
particularly	O
with	O
breastfeeding	O
,	O
this	O
observation	O
provides	O
a	O
further	O
basis	O
for	O
promoting	O
use	O
of	O
expressed	O
breastmilk	O
in	O
premature	O
infants	O
,	O
a	O
known	O
preventative	O
measure	O
to	O
prevent	O
NEC	B-DS
.	O

In	O
future	O
studies	O
,	O
PSA	O
could	O
also	O
be	O
used	O
in	O
a	O
clinical	O
trial	O
as	O
a	O
“	O
pioneer	O
”	O
bacterial	O
product	O
for	O
premature	O
infants	O
to	O
prevent	O
NEC	B-DS
.	O

Supporting	O
information	O

Individual	O
data	O
points	O
used	O
to	O
build	O
all	O
the	O
figures	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

